专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2006083964A2 MODIFIED FUSION MOLECULES FOR TREATMENT OF ALLERGIC DISEASE 审中-公开
标题翻译：用于治疗过敏性疾病的改良融合分子
公开(公告)号：WO2006083964A2
公开(公告)日：2006-08-10
申请号：PCT/US2006/003562
申请日：2006-01-31
申请人： THE REGENTS OF THE UNIVERSITY OF CALIFORNIA , SAXON, Andrew , ZHANG, Ke , ZHU, Daocheng
发明人： SAXON, Andrew , ZHANG, Ke , ZHU, Daocheng
IPC分类号： A61K39/395 , C07H21/04 , C12P21/06 , C07K16/42
CPC分类号： C07K16/00 , C07K2317/52 , C07K2319/30 , Y10S530/866 , Y10S530/868
摘要： The present invention comprises a fusion molecule comprising a Fee fragment sequenc including functionally active CH2, CH3 and CH4 domains of the constant region of an IgE heavy chain (CHe2-CHe3-CHe4 sequence) linked at its C-terminus to the N-terminus of a second polypeptide including functionally active hinge, CH2 and CH3 domains of the constant region of an IgG 1 heavy chain (γhinge-CHγ2-CHγ3 sequence), pharmaceutical compositions comprising the fusion molecule and methods of treatment using the fusion molecule.
摘要翻译：本发明包括融合分子，其包含费用片段序列，其包含在其C末端至N-末端连接的IgE重链（CHe2-CHe3-CHe4序列）恒定区的功能活性CH 2，CH 3和CH 4结构域包含IgG1重链（α铰链-CH2-CH2→3序列）恒定区的功能活性铰链，CH2和CH3结构域的第二多肽，包含融合分子的药物组合物和使用融合分子的治疗方法。

2. 发明申请

WO2002088317A3 FUSION MOLECULES AND METHODS FOR TREATMENT OF IMMUNE DISEASES 审中-公开
公开(公告)号：WO2002088317A3
公开(公告)日：2002-11-07
申请号：PCT/US2002/013527
申请日：2002-05-01
申请人： THE REGENTS OF THE UNIVERSITY OF CALIFORNIA , SAXON, Andrew , ZHANG, Ke , ZHU, Daocheng
发明人： SAXON, Andrew , ZHANG, Ke , ZHU, Daocheng
IPC分类号： A61K39/00
摘要： The invention concerns bifunctional fusion molecules, and novel, safer and more efficacious methods for the treatment of immune disorders resulting from excessive or unwanted immune responses. The invention provides methods for the suppression of type I hypersensitive (i.e., IgE-mediated) allergic conditions, methods for the prevention of anaphylactic responses that occur as a result of traditional peptide immunotherapies for allergic and autoimmune disorders, and provides novel methods for the treatment of autoimmune conditions, where the methods have reduced risk of triggering an anaphylactic response. The invention provides novel therapeutic approaches for the treatment of allergic responses, including the prevention of anaphylactic response that can occur from environmental allergen exposure. The invention also provides methods for the treatment of autoimmune disorders such as multiple sclerosis, autoimmune type I diabetes mellitus, and rheumatoid arthritis. The invention also provides methods for preventing anaphylactic response during traditional antigen therapies.

3. 发明申请

WO2006083964A3 MODIFIED FUSION MOLECULES FOR TREATMENT OF ALLERGIC DISEASE 审中-公开
标题翻译：用于治疗过敏性疾病的改良融合分子
公开(公告)号：WO2006083964A3
公开(公告)日：2009-04-30
申请号：PCT/US2006003562
申请日：2006-01-31
申请人： UNIV CALIFORNIA , SAXON ANDREW , ZHANG KE , ZHU DAOCHENG
发明人： SAXON ANDREW , ZHANG KE , ZHU DAOCHENG
IPC分类号： A61K39/00 , A61K39/395 , C07H21/04 , C07K16/00 , C12N5/12 , C12P21/08
CPC分类号： C07K16/00 , C07K2317/52 , C07K2319/30 , Y10S530/866 , Y10S530/868
摘要： The present invention comprises a fusion molecule comprising a Fee fragment sequenc including functionally active CH2, CH3 and CH4 domains of the constant region of an IgE heavy chain (CHe2-CHe3-CHe4 sequence) linked at its C-terminus to the N-terminus of a second polypeptide including functionally active hinge, CH2 and CH3 domains of the constant region of an IgG 1 heavy chain (?hinge-CH?2-CH?3 sequence), pharmaceutical compositions comprising the fusion molecule and methods of treatment using the fusion molecule.
摘要翻译：本发明包括融合分子，其包含费用片段序列，其包含在其C末端至N-末端连接的IgE重链（CHe2-CHe3-CHe4序列）恒定区的功能活性CH 2，CH 3和CH 4结构域包含IgG 1重链（α铰链-CH2-CH2→3序列）恒定区的功能活性铰链，CH2和CH3结构域的第二多肽，包含该融合分子的药物组合物和使用该融合分子的治疗方法。

4. 发明申请

WO2002088317A2 FUSION MOLECULES AND METHODS FOR TREATMENT OF IMMUNE DISEASES 审中-公开
标题翻译：融合分子和治疗免疫缺陷病的方法
公开(公告)号：WO2002088317A2
公开(公告)日：2002-11-07
申请号：PCT/US2002/013527
申请日：2002-05-01
申请人： REGENTS OF THE UNIVERSITY OF CALIFORNIA , SAXON, Andrew , ZHANG, Ke , ZHU, Daocheng
发明人： SAXON, Andrew , ZHANG, Ke , ZHU, Daocheng
IPC分类号： C12N
CPC分类号： C07K16/00 , A61K2039/505 , C07K2317/52 , C07K2319/00
摘要： The invention concerns bifunctional fusion molecules, and novel, safer and more efficacious methods for the treatment of immune disorders resulting from excessive or unwanted immune responses. The invention provides methods for the suppression of type I hypersensitive (i.e., IgE-mediated) allergic conditions, methods for the prevention of anaphylactic responses that occur as a result of traditional peptide immunotherapies for allergic and autoimmune disorders, and provides novel methods for the treatment of autoimmune conditions, where the methods have reduced risk of triggering an anaphylactic response. The invention provides novel therapeutic approaches for the treatment of allergic responses, including the prevention of anaphylactic response that can occur from environmental allergen exposure. The invention also provides methods for the treatment of autoimmune disorders such as multiple sclerosis, autoimmune type I diabetes mellitus, and rheumatoid arthritis. The invention also provides methods for preventing anaphylactic response during traditional antigen therapies.
摘要翻译：本发明涉及双功能融合分子，以及用于治疗由过度或不需要的免疫应答引起的免疫疾病的新型，更安全和更有效的方法。本发明提供抑制I型过敏（即IgE介导的）变态反应病症的方法，用于预防因过敏性和自身免疫性疾病的传统肽免疫治疗而发生的过敏反应的方法，并提供新的治疗方法的自身免疫病症，其中方法降低了触发过敏反应的风险。本发明提供了用于治疗过敏反应的新型治疗方法，包括预防由环境变应原暴露引起的过敏反应。本发明还提供了治疗自身免疫性疾病如多发性硬化，自身免疫性I型糖尿病和类风湿性关节炎的方法。本发明还提供了用于在传统抗原治疗期间预防过敏反应的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式